Titan Pharmaceuticals, Inc. (TTNP)
Volume here is strong and the chart tells it all. See this:
When you look at the chart you can obviously see that the company had a huge sell-off in early May as the company received bad news from the FDA on Probuphine. The FDA requested additional information as stated in the April 30th press release.
These things are never easy. To help ease investors minds the company issued its release on May 29th. In it they announced an amended agreement with Braeburn Pharmaceuticals Sprl.
What is Probuphine?
Probuphine has been shown to be effective with an acceptable safety profile in the following clinical studies:
- Two six-month, double-blind, placebo-controlled safety and efficacy trials; one of which included an open label, active control (Suboxone). In both studies, Probuphine demonstrated superiority to placebo implants, and in the second study, established non-inferiority in comparison to Suboxone.
- Two six-month, open-label re-treatment safety trials; and
- A pharmacokinetic (relative bioavailability) safety study.